Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 53

1.

Structure-based strategies for drug design and discovery.

Kuntz ID.

Science. 1992 Aug 21;257(5073):1078-82. Review.

PMID:
1509259
2.

Importance of molecular computer modeling in anticancer drug development.

Geromichalos GD.

J BUON. 2007 Sep;12 Suppl 1:S101-18. Review.

PMID:
17935268
3.

[Development of antituberculous drugs: current status and future prospects].

Tomioka H, Namba K.

Kekkaku. 2006 Dec;81(12):753-74. Review. Japanese.

PMID:
17240921
4.

Development of antiviral drugs for the treatment of AIDS: strategies and prospects.

Haseltine WA.

J Acquir Immune Defic Syndr. 1989;2(4):311-34. Review.

PMID:
2666638
5.

New approaches to drug discovery and development: a mechanism-based approach to pharmaceutical research and its application to BNP7787, a novel chemoprotective agent.

Hausheer FH, Kochat H, Parker AR, Ding D, Yao S, Hamilton SE, Petluru PN, Leverett BD, Bain SH, Saxe JD.

Cancer Chemother Pharmacol. 2003 Jul;52 Suppl 1:S3-15. Epub 2003 Jun 18. Review.

PMID:
12819940
6.

Discovery and in vitro development of AIDS antiviral drugs as biopharmaceuticals.

Rice WG, Bader JP.

Adv Pharmacol. 1995;33:389-438. Review.

PMID:
7495676
7.

Molecular targets for AIDS therapy.

Mitsuya H, Yarchoan R, Broder S.

Science. 1990 Sep 28;249(4976):1533-44. Review.

PMID:
1699273
8.

Design and structure of peptide and peptidomimetic antagonists of protein-protein interaction.

Sillerud LO, Larson RS.

Curr Protein Pept Sci. 2005 Apr;6(2):151-69. Review.

PMID:
15853652
9.

The 3-D structure of HIV-1 proteinase and the design of antiviral agents for the treatment of AIDS.

Blundell TL, Lapatto R, Wilderspin AF, Hemmings AM, Hobart PM, Danley DE, Whittle PJ.

Trends Biochem Sci. 1990 Nov;15(11):425-30. Review.

PMID:
2278102
10.

New strategies for treating AIDS.

Sandstrom PA, Folks TM.

Bioessays. 1996 May;18(5):343-6. Review.

PMID:
8639156
11.

Structure-based inhibitor design.

Craig SP 3rd, Eakin AE.

Vitam Horm. 2000;58:149-69. Review.

PMID:
10668398
12.

Inhibitors of FabI, an enzyme drug target in the bacterial fatty acid biosynthesis pathway.

Lu H, Tonge PJ.

Acc Chem Res. 2008 Jan;41(1):11-20. doi: 10.1021/ar700156e. Review.

PMID:
18193820
13.

Inhibitors of HIV-1 reverse transcriptase and integrase: classical and emerging therapeutical approaches.

Tarrago-Litvak L, Andreola ML, Fournier M, Nevinsky GA, Parissi V, de Soultrait VR, Litvak S.

Curr Pharm Des. 2002;8(8):595-614. Review.

PMID:
11945161
14.

HIV-1 integrase: the next target for AIDS therapy?

d'Angelo J, Mouscadet JF, Desmaƫle D, Zouhiri F, Leh H.

Pathol Biol (Paris). 2001 Apr;49(3):237-46. Review.

PMID:
11367559
15.

New developments in diketo-containing inhibitors of HIV-1 integrase.

Zhao G, Wang C, Liu C, Lou H.

Mini Rev Med Chem. 2007 Jul;7(7):707-25. Review.

PMID:
17627583
17.

Exploiting current understanding of antibiotic action for discovery of new drugs.

Chopra I, Hesse L, O'Neill AJ.

Symp Ser Soc Appl Microbiol. 2002;(31):4S-15S. Review.

PMID:
12481824
18.
19.

Peptide and non-peptide HIV fusion inhibitors.

Jiang S, Zhao Q, Debnath AK.

Curr Pharm Des. 2002;8(8):563-80. Review.

PMID:
11945159
20.

Present status and future prospects for HIV therapies.

Johnston MI, Hoth DF.

Science. 1993 May 28;260(5112):1286-93. Review.

PMID:
7684163

Supplemental Content

Support Center